Stevanato Group

Stevanato Group

The Stevanato Group originated as a one-room glassmaking shop in the Veneto region, producing ampules and later pre-sterilized syringes as global vaccine demand surged. Giovanni Stevanato's descendants — principally his sons Franco, Sergio, and Marco — expanded the business into a multinational that supplies over 40 countries, counting Pfizer, Roche, and Novartis as customers. The family wealth is therefore rooted in a manufacturing enterprise that became critical infrastructure for the pharmaceutical industry, particularly during the COVID-19 vaccine rollout, when Stevanato's pre-fillable syringe systems were contracted by multiple vaccine developers. The family office's investment posture mirrors the operating business: direct, industrial, and concentrated on healthcare packaging and life-sciences equipment. While precise deployment numbers are not public, the family has historically re-invested operating profits into plant expansions across Italy, China, Germany, and the United States rather than diversifying into unrelated third-party funds. This is a manufacturing-first mentality — capital allocated to glass-tubing plants, inspection machines, and assembly lines rather than limited-partner positions in venture capital. The IPO on NYSE in July 2021, managed by Morgan Stanley and BofA, demonstrated the family's willingness to tap public markets for growth capital while maintaining a lock on governance. Post-IPO, the Stevanato family controls approximately 80% of voting power through a dual-class share structure, with Franco Stevanato serving as Chairman Emeritus. Headcount across the operating group exceeds 5,000 employees globally, with recent expansions including a new US facility in Fishers, Indiana, announced in 2023. The family's adjacent philanthropic vehicles are not formally separated into a named foundation, but the group's regional footprint in the Veneto suggests significant local employment and municipal ties typical of Italian industrial dynasties. Structurally, the family office is unusual for being embedded within a public company rather than cordoned off as a separate entity. This blurring of corporate treasury and family-office functions means the family's investment program is effectively the company's capital-expenditure plan — an identity that makes third-party allocators mostly irrelevant. The governance structure, with multiple second-generation brothers holding vice-chair roles, presents a succession question typical of European industrial families: whether the third generation will professionalize the office or continue to run it as a founder-operator vehicle.